Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

To join this study, you would need to be an adult between 18 and 90 years old and have a diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM). This includes both the inherited form of the condition and the 'wild-type' form that isn't passed down in families. Doctors will check that your heart's main wall is at least 12mm thick and that a specific blood test, called NT-proBNP, is above a certain level, indicating some heart strain.

You should also have been taking a 'loop diuretic' medicine, which helps remove excess fluid from your body, for at least a month before the study starts. You would need to have symptoms of heart failure that doctors classify as NYHA Class II to IV. Lastly, your doctor would need to believe that you are likely to live for at least another six months. If you are a woman who could become pregnant, or a man whose partner could become pregnant, you would need to use reliable contraception throughout the study.

There are also reasons why you might not be able to join. For example, if you have other types of amyloidosis, like AL or AA amyloidosis, or a specific brain condition called leptomeningeal amyloidosis. You also couldn't join if you’ve had a heart attack, severe chest pain, stroke, or heart surgery in the last three months, or if you have a very fast or irregular heartbeat that isn't under control. Other reasons include very poor kidney function, a severely weakened heart pump (LVEF less than 30%), or severe nerve damage from the condition.

If you decide to take part in this study, you would receive either the study medicine, ALXN2220, or a placebo (a dummy treatment). You would have regular visits to the clinic for check-ups, which would include physical examinations, blood tests, and heart tests like echocardiograms (ultrasound scans of your heart) and ECGs (heart tracings). These visits allow the study team to monitor your health, see how you're responding to the treatment, and check for any side effects.

The specific number and frequency of visits will be explained in detail by the study team, but generally, clinical trials involve several visits over a period of time to gather enough information. You would also be asked to keep track of any symptoms or changes in your health between visits. The total duration of your participation in the study, including follow-up, would be carefully explained to you before you make any decision to join.